Exercise Target Brain Oscillations in Psychosis

Sponsor
University of Minnesota (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT05338424
Collaborator
(none)
40
1
24
1.7

Study Details

Study Description

Brief Summary

Previous studies have shown that cardiorespiratory fitness (how well the heart and lungs are able to function during physical activity) is often reduced in people with psychosis. The goal of this research study is to test the hypothesis that aerobic exercise can lead to small changes in brain functioning that can influence visual perception and attention in psychosis. The type of aerobic exercise used in this study is called Sprint Interval Training, or "SIT". Information from this study will help to develop interventions that enhance cognition and maximize the quality of life for persons living with psychosis.

The exercise procedure used is called SIT, which involves training rigorously on a stationary bike for a short period of time followed by a resting period.

Condition or Disease Intervention/Treatment Phase
  • Other: Sprint Interval Training (SIT)

Study Design

Study Type:
Observational
Anticipated Enrollment :
40 participants
Observational Model:
Case-Crossover
Time Perspective:
Prospective
Official Title:
Sprint Interval Training to Target Brain Oscillations in Psychosis
Anticipated Study Start Date :
Jul 1, 2022
Anticipated Primary Completion Date :
Jun 30, 2024
Anticipated Study Completion Date :
Jun 30, 2024

Arms and Interventions

Arm Intervention/Treatment
Sprint Interval Training (SIT)

The 1-session SIT protocol will include "Work" bouts performed at maximal intensity targets. Three "Work" bouts will be performed at 20-second intervals separated by 2 recovery bouts consisting of 2 minutes of low-intensity cycling. The SIT session will employ a standardized warm up and cool down of 3 minutes at a self-selected light intensity, per current guidelines. SIT sessions will take 15 minutes to complete.

Other: Sprint Interval Training (SIT)
Active arm-- exercise dictated by protocol

Stretching

Stretching will include a low-intensity range of motion and stretching exercises with session duration (15 minutes) being matched to SIT.

Outcome Measures

Primary Outcome Measures

  1. Change in Individual Alpha Frequency [through study completion, on average 2 weeks]

    A prominent neural oscillatory rhythm measured from resting EEG.

  2. Change in Visual Attention [through study completion, on average 2 weeks]

    Computerized tasks that measure speeded sustained attention.

  3. Change in Visual Perception [through study completion, on average 2 weeks]

    Computerized tasks that measure speeded visual perception

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 64 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Meet diagnostic criteria for schizophrenia or schizoaffective disorder

  • Are age 18-64

  • Fluent in written and spoken English

  • Have an outpatient status of at least 1 month prior to participation

  • Has been on a stable dose of psychiatric medication for at least one month prior to participation (titration to a lower dose of psychotropic medications under supervision of a psychiatrist can be allowed at the discretion of the investigators)

Exclusion Criteria:
  • Current or possibility of current pregnancy (self-reported)

  • Active suicidal ideation at screening or baseline assessments, or previous intent to act on suicidal ideation with a specific plan, preparatory acts, or an actual suicide attempt within the last 3 months, as indicated by the C-SSRS

  • WTAR standardized score below 70

  • American College of Sports Medicine contraindication to exercise

Contacts and Locations

Locations

Site City State Country Postal Code
1 University of Minnesota Minneapolis Minnesota United States 55455

Sponsors and Collaborators

  • University of Minnesota

Investigators

  • Principal Investigator: Ian Ramsay, University of Minnesota

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
University of Minnesota
ClinicalTrials.gov Identifier:
NCT05338424
Other Study ID Numbers:
  • PSYCH-2022-30666
First Posted:
Apr 21, 2022
Last Update Posted:
Apr 21, 2022
Last Verified:
Apr 1, 2022
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by University of Minnesota
Additional relevant MeSH terms:

Study Results

No Results Posted as of Apr 21, 2022